Literature DB >> 3385740

Intrafamilial clinical variability of type 1 Gaucher disease in a French-Canadian family.

F Y Choy1.   

Abstract

Glucocerebroside beta-glucosidase (glucocerebrosidase) activity was determined from peripheral blood lymphocytes and cultured skin fibroblasts of eight full sibs in a French-Canadian family at risk for Gaucher disease, an autosomal recessive sphingolipidosis resulting from deficient glucocerebrosidase activity. The diagnosis of type 1, non-neuronopathic Gaucher disease was made in all of the five affected sibs on the basis of deficient (7.5 to 15.5% of control mean) glucocerebrosidase activity and absence of neurological involvement. Normal levels of enzyme activity were found in two of the three asymptomatic sibs. The third asymptomatic sib had an intermediate level (about 50% of control mean) of fibroblast and lymphocyte glucocerebrosidase activity, indicating that he is a carrier. Considerable clinical heterogeneity was noted among the five affected sibs. One patient is mildly affected and so far has not developed any orthopaedic complications associated with Gaucher disease. His haematological complications were also reversed after splenectomy 24 years ago. In contrast to this mild presentation, the patient's splenectomised sister has been very anaemic and thrombocytopenic. There have been severe orthopaedic complications associated with Gaucher disease, including vertebral compression, avascular necrosis, and pathological fracture of the long bones. The clinical picture of the other three affected sibs appeared to vary between the two extremes. Although the asymptomatic parents of the patients died many years ago, their heterozygous status with respect to Gaucher disease can be deduced by the presence of Gaucher homozygotes, normal homozygotes, and one heterozygote among their eight offspring. Present findings suggest that the clinical variability of type 1 Gaucher disease may be attributed to variable expressions of the same Gaucher mutant alleles, in addition to the presence of multiple mutant alleles that are widely disseminated in the population.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3385740      PMCID: PMC1050458          DOI: 10.1136/jmg.25.5.322

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  7 in total

1.  METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.

Authors:  R O BRADY; J N KANFER; D SHAPIRO
Journal:  Biochem Biophys Res Commun       Date:  1965-01-18       Impact factor: 3.575

2.  Gaucher disease: the effects of phosphatidylserine on glucocerebrosidase from normal and Gaucher fibroblasts.

Authors:  F Y Choy
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

3.  Genetic heterogeneity in Gaucher disease.

Authors:  J Zlotogora; R Zaizov; C Klibansky; Y Matoth; G Bach; T Cohen
Journal:  J Med Genet       Date:  1986-08       Impact factor: 6.318

4.  In situ radiation-inactivation size of fibroblast membrane-bound acid beta-glucosidase in Gaucher type 1, type 2 and type 3 disease.

Authors:  F Y Choy; M Woo; M Potier
Journal:  Biochim Biophys Acta       Date:  1986-03-07

5.  Gaucher disease: accurate identification of asymptomatic French-Canadian carrier using nonlabeled authentic sphingolipid substrate N-palmitoyl dihydroglucocerebroside.

Authors:  F Y Choy; L Bouillon; C A Laurin
Journal:  Am J Med Genet       Date:  1987-08

6.  Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants.

Authors:  O Nilsson; G A Grabowski; M D Ludman; R J Desnick; L Svennerholm
Journal:  Clin Genet       Date:  1985-05       Impact factor: 4.438

7.  Gaucher disease: comparative study of acid phosphatase and glucocerebrosidase in normal and type-1 Gaucher tissues.

Authors:  F Y Choy
Journal:  Am J Med Genet       Date:  1985-07
  7 in total
  6 in total

1.  Enzyme replacement therapy for Gaucher's disease: the early Canadian experience.

Authors:  J J MacKenzie; D Amato; J T Clarke
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

Review 2.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

Review 3.  Laboratory and genetic evaluation of Gaucher disease.

Authors:  Olaf A Bodamer; Christina Hung
Journal:  Wien Med Wochenschr       Date:  2010-08-16

Review 4.  Alglucerase. A review of its therapeutic use in Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

5.  Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.

Authors:  Karen E Murphy; Amanda M Gysbers; Sarah K Abbott; Nahid Tayebi; Woojin S Kim; Ellen Sidransky; Antony Cooper; Brett Garner; Glenda M Halliday
Journal:  Brain       Date:  2014-01-28       Impact factor: 13.501

6.  Nine-year experience in Gaucher disease diagnosis at the Spanish reference center Fundación Jiménez Díaz.

Authors:  N V Ortiz-Cabrera; J Gallego-Merlo; C Vélez-Monsalve; R de Nicolas; S Fontao Mas; C Ayuso; M J Trujillo-Tiebas
Journal:  Mol Genet Metab Rep       Date:  2016-11-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.